JP2016041071A5 - - Google Patents

Download PDF

Info

Publication number
JP2016041071A5
JP2016041071A5 JP2015204285A JP2015204285A JP2016041071A5 JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5 JP 2015204285 A JP2015204285 A JP 2015204285A JP 2015204285 A JP2015204285 A JP 2015204285A JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5
Authority
JP
Japan
Prior art keywords
expression level
patient
beneficial response
gbp1
rna transcript
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015204285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016041071A (ja
JP6190434B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016041071A publication Critical patent/JP2016041071A/ja
Publication of JP2016041071A5 publication Critical patent/JP2016041071A5/ja
Application granted granted Critical
Publication of JP6190434B2 publication Critical patent/JP6190434B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015204285A 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー Expired - Lifetime JP6190434B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56103504P 2004-04-09 2004-04-09
US60/561,035 2004-04-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013103045A Division JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Publications (3)

Publication Number Publication Date
JP2016041071A JP2016041071A (ja) 2016-03-31
JP2016041071A5 true JP2016041071A5 (enExample) 2016-09-08
JP6190434B2 JP6190434B2 (ja) 2017-08-30

Family

ID=34981928

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2015204285A Expired - Lifetime JP6190434B2 (ja) 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Country Status (9)

Country Link
US (2) US7871769B2 (enExample)
EP (4) EP2947160B1 (enExample)
JP (3) JP5813908B2 (enExample)
AU (2) AU2005233593B2 (enExample)
CA (2) CA2563074C (enExample)
DK (1) DK2163650T3 (enExample)
ES (2) ES2636470T3 (enExample)
IL (4) IL178508A (enExample)
WO (1) WO2005100606A2 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
JP2007530075A (ja) * 2004-04-23 2007-11-01 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がんの予後診断のための組成物および方法
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CN102747140A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
JP2008017832A (ja) * 2006-06-13 2008-01-31 Sysmex Corp がんの転移の判定方法及び判定装置
US20080076134A1 (en) * 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
CA2680591A1 (en) * 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
EP2228457A1 (en) * 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
JP2009050189A (ja) * 2007-08-24 2009-03-12 Sumitomo Bakelite Co Ltd 抗癌剤の有効性予測方法
CA2699385A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
US8168755B2 (en) * 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
EP2294215B1 (en) * 2008-05-12 2013-01-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
AU2009253675A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
ES2606703T3 (es) * 2008-07-15 2017-03-27 Epigenomics Ag Método para predecir el pronóstico de una terapia de cáncer de mama con base en el análisis de metilación del gen
KR100996994B1 (ko) * 2008-08-18 2010-11-25 울산대학교 산학협력단 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법
WO2010022268A2 (en) * 2008-08-20 2010-02-25 The Regents Of The University Of Colorado, A Body Corporate Markers for assessing the susceptibility of cancer to igf-1r treatment
JP2010057486A (ja) * 2008-09-02 2010-03-18 Sysmex Corp 化学療法に対するがん患者の応答の予測方法
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2373809A1 (en) * 2008-12-10 2011-10-12 Ipsogen Methods for identifying erbb2 alteration in tumors
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2010091296A2 (en) * 2009-02-06 2010-08-12 The Regents Of The University Of California Emx2 in cancer diagnosis and prognosis
US8972899B2 (en) 2009-02-10 2015-03-03 Ayasdi, Inc. Systems and methods for visualization of data analysis
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US20130203059A1 (en) * 2010-07-02 2013-08-08 Topogen, Inc. Method for Diagnosis of Bladder Cancer and Related Kits
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
TW201209163A (en) * 2010-07-12 2012-03-01 Opko Curna Llc Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
CN103415624B (zh) 2010-08-13 2017-03-01 私募蛋白质体公司 胰腺癌生物标记及其用途
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
PL2619576T3 (pl) * 2010-09-24 2021-07-05 Niels Grabe Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP5828446B2 (ja) * 2011-02-10 2015-12-09 国立大学法人秋田大学 扁平上皮癌組織の放射線感受性マーカー
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
EP2705370A2 (en) * 2011-05-06 2014-03-12 Xentech Markers for cancer prognosis and therapy and methods of use
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
WO2012174203A2 (en) * 2011-06-14 2012-12-20 Anthony Albino Methods and kits for the detection and treatment of recurring prostate cancer
EP2834640B1 (en) * 2011-10-04 2020-06-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
WO2013055704A1 (en) * 2011-10-10 2013-04-18 Ayasdi, Inc. Systems and methods for mapping new patient information to historic outcomes for treatment assistance
JP6144695B2 (ja) * 2011-11-30 2017-06-07 ユニバーシティー オブ ノースカロライナ アット チャペル ヒル タキサン療法を用いて乳癌を処置する方法
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2794924B1 (en) 2011-12-22 2019-02-06 Baylor Research Institute Identification of mirna signatures in human colorectal cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
DK3179393T3 (da) 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
FR2987446B1 (fr) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis Test diagnostic de la resistance a l'azacitidine
WO2013170174A1 (en) 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
WO2014085653A1 (en) * 2012-11-30 2014-06-05 Celera Corporation Multi-gene signatures for predicting response to chemotherapy or risk of metastasis for breast cancer
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US10240206B2 (en) * 2013-02-01 2019-03-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarkers and methods for predicting benefit of adjuvant chemotherapy
KR102241063B1 (ko) 2013-03-15 2021-04-16 얀센 파마슈티카 엔.브이. 예측성 바이오마커에 대한 검정법
MX369911B (es) * 2013-05-30 2019-11-26 Genomic Health Inc Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
DK3134119T3 (en) * 2014-04-24 2018-10-22 Pfizer CANCER TREATMENT
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
BR112017007962A2 (pt) * 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
CA2965217A1 (en) * 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
KR102116485B1 (ko) 2015-01-20 2020-05-28 난토믹스, 엘엘씨 고분화 방광암의 화학요법에 대한 반응 예측을 위한 시스템들 및 방법들
EP3362563A1 (en) 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
US20190018017A1 (en) * 2015-12-10 2019-01-17 Nantomics, Llc Integrated Analysis To Determine Prognosis After Treatment For Primary Breast Cancer
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
JP7132911B2 (ja) 2016-09-16 2022-09-07 バイオ－パス ホールディングス， インコーポレイテッド リポソームアンチセンスオリゴヌクレオチドとの併用療法
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION
IL269608B2 (en) 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
RU2675236C1 (ru) * 2018-02-22 2018-12-18 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных раком молочной железы
US12174192B2 (en) * 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US20220357328A1 (en) * 2019-09-09 2022-11-10 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN111184865B (zh) * 2020-03-09 2021-11-16 复旦大学附属金山医院 Stat1在耐紫杉醇上皮性卵巢癌治疗中的用途
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
EP4623092A1 (en) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease
WO2025171441A1 (en) * 2024-02-13 2025-08-21 The Council Of The Queensland Institute Of Medical Research Prognostic signature for cancer recurrence and responsiveness

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
KR100459052B1 (ko) * 1995-12-18 2005-01-15 서젠, 인크. Aur-1및(또는)aur-2관련질병의진단및치료
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
ATE414149T1 (de) * 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
DE19922052A1 (de) * 1999-05-14 2000-11-16 Theragen Molekularmedizinische Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
WO2001025250A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2491433A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) * 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
CA2398107C (en) * 2000-01-28 2013-11-19 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US7157227B2 (en) * 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03000575A (es) * 2000-07-21 2004-12-13 Global Genomics Ab Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2001278011A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002008765A2 (en) 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
JP4368110B2 (ja) * 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
WO2002070741A2 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
KR20030094281A (ko) 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20030077582A1 (en) * 2001-03-27 2003-04-24 Wen-Lin Kuo Methods for diagnosing and monitoring malignancies by screeining gene copy numbers
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20030124130A1 (en) * 2002-01-02 2003-07-03 Brown Robert E. Proteomic analysis of tumors for development of consultative report of therapeutic options
AU2003201741A1 (en) * 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004074518A1 (en) 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US10066268B2 (en) 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
EP1759009A1 (en) * 2004-05-28 2007-03-07 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2228457A1 (en) 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2294215B1 (en) 2008-05-12 2013-01-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
MX337650B (es) 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.

Similar Documents

Publication Publication Date Title
JP2016041071A5 (enExample)
Khan et al. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer
Nassar et al. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Kachalaki et al. Cancer chemoresistance; biochemical and molecular aspects: a brief overview
JP2016174600A5 (enExample)
JP2017055769A5 (enExample)
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
BR112012024718A2 (pt) método para a predição da recorrência de câncer da mama sob tratamento endócrino
JP2007507222A5 (enExample)
JP2010538609A5 (enExample)
WO2016172710A3 (en) Methods and reagents for determination and treatment of organotropic metastasis
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
WO2019075251A3 (en) Cancer score for assessment and response prediction from biological fluids
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
JP2016521979A5 (enExample)
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
Su et al. Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression
JP2017536085A5 (enExample)
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
Nikolova et al. 52P MiRNA profile associated with the invasiveness in non-functioning pituitary adenomas
Wang et al. The Long Noncoding RNA SPRY4-IT1 Contributes to proliferation of Human breast cancer Cells via upregualtion of ZNF703 Expression
Dai et al. Machine learning models for predicting lymph node and distant metastases in colorectal cancer
Albain et al. Proceedings of the first global workshop on breast cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer
Kutszegi et al. Monitoring the potential role of circulating miR-181b-5p in minimal residual disease in paediatric acute lymphoblastic leukaemia